×
Cronos Group Total Long-Term Assets 2017-2024 | CRON
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Cronos Group total long-term assets from 2017 to 2024. Total long-term assets can be defined as the sum of all assets classified as non-current
View More
Cronos Group Total Long-Term Assets 2017-2024 | CRON
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Cronos Group total long-term assets from 2017 to 2024. Total long-term assets can be defined as the sum of all assets classified as non-current
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$79.8B
Takeda Pharmaceutical (TAK)
$42.6B
Sandoz Group AG (SDZNY)
$19.5B
Merck (MKKGY)
$19.1B
Astellas Pharma (ALPMY)
$18.3B
United Therapeutics (UTHR)
$16.6B
Summit Therapeutics (SMMT)
$14B
Neurocrine Biosciences (NBIX)
$12.7B
Shionogi (SGIOY)
$12B
Catalent (CTLT)
$11.1B
Madrigal Pharmaceuticals (MDGL)
$7.6B
Orion OYJ (ORINY)
$6.7B
Corcept Therapeutics (CORT)
$6B
Ionis Pharmaceuticals (IONS)
$5.4B
Crinetics Pharmaceuticals (CRNX)
$5.2B
PTC Therapeutics (PTCT)
$3.3B
Dyne Therapeutics (DYN)
$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.6B
Soleno Therapeutics (SLNO)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2.2B
NewAmsterdam Pharma (NAMS)
$1.9B
Xencor (XNCR)
$1.8B
Recursion Pharmaceuticals (RXRX)
$1.6B
Evotec AG (EVO)
$1.6B
BioCryst Pharmaceuticals (BCRX)
$1.6B
Harrow (HROW)
$1.5B
Indivior (INDV)
$1.5B
Guardian Pharmacy Services (GRDN)
$1.5B
Ocular Therapeutix (OCUL)
$1.4B